In OLYMPIAD, a total of 295 patients (7 of which were MaBC patients with BRCA-mutated HER2-negative metastatic disease) were enrolled to receive either an oral PARP inhibitor olaparib or a physician's choice single-agent chemotherapy (TPC). This evidence concerns the gene ERBB2 and metastatic neoplasm.